In less than 1.5 sessions, Moderna recovered the slide from FDA decision to further analyze the data on Adolescents' doses and its own decision not to file for EUA ok Kids' doses. Both if these become future catalysts and steady increase in SP with progressive advance in research, pipelines' development and commercialization of the Adolescents & Kids Cov Vaxes as well as future contracts for 2022 and 2023 are bullish signs and IMO the earnings' beat on Thursday will boost the SP. Otherwise, the marathon continues with some pacing adjustments.
this is a good news, what do you think?$Moderna, Inc.(MRNA)$
精彩评论